In the past, RBPs were considered largely ‘undruggable’ because of the lack of enzymatic pockets typically targeted by small molecules, the high structural similarity between individual members of RBD families and the significant fraction of unstructured regions present in these proteins. Here, we will pursue various strategies for targeting RBPs, including using the high-capacity infrastructures owned by INNOPHARMA (part of KAETOR, Associate Partner SME), one of the seven high-capacity nodes of the European Research Infrastructure Consortium (ERIC) EU-OPENSCREEN.
